Novel Fluorinated Spermine and Small Molecule PEI to Deliver Anti-PD-L1 and Anti-VEGF siRNA for Highly Efficient Tumor Therapy.

Pharmaceutics

Engineering Research Center of Cell & Therapeutic Antibody, Ministry of Education, School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, China.

Published: December 2021

Small interfering RNA (siRNA) can specifically silence disease gene expression. This project investigated the overexpression of programmed death receptor ligand 1 (PD-L1) and vascular endothelial growth factor (VEGF) on the surface of tumor cells. However, the main obstacle to the development of gene therapy drugs is the lack of an efficient delivery vector, which should be able to overcome multiple delivery barriers and protect siRNA to enter the target cells. Therefore, a novel fluorine-modified endogenous molecular carrier TFSPEI was constructed by linking fluorinated groups with hydrophobic and hydrophilic characteristics on the surface of PEI and spermine. The results showed that lower toxicity, higher endocytosis, and silencing efficiency were achieved. We found that the inhibition of VEGF targets can indirectly activate the immune response to promote the tumor-killing and invasion effects of T cells. The combined delivery of anti-VEGF siRNA and anti-PD-L1 siRNA could inhibit the expression of corresponding proteins, restore the anti-tumor function of T cells and inhibit the growth of neovascularization, and obtained significant anti-tumor effects. Therefore, this safe and efficient fluorinated spermine and small molecule PEI-based anti-PD-L1 and anti-VEGF siRNA delivery system is expected to provide a new strategy for gene therapy of tumors.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8708240PMC
http://dx.doi.org/10.3390/pharmaceutics13122058DOI Listing

Publication Analysis

Top Keywords

anti-vegf sirna
12
fluorinated spermine
8
spermine small
8
small molecule
8
anti-pd-l1 anti-vegf
8
gene therapy
8
sirna
6
novel fluorinated
4
molecule pei
4
pei deliver
4

Similar Publications

Article Synopsis
  • * The study discovered that anti-VEGF drugs like bevacizumab, ranibizumab, and aflibercept promote epithelial-mesenchymal transition (EMT) in retinal cells, increasing the levels of CCN2, a pro-fibrotic factor.
  • * Co-treatment with CCN5, which inhibits CCN2, mitigated the negative effects of anti-VEGF drugs, indicating that targeting these pathways could improve treatment outcomes for nAMD.
View Article and Find Full Text PDF

Available Therapeutic Options for Corneal Neovascularization: A Review.

Int J Mol Sci

May 2024

Department of Ophthalmology, Prof. K. Gibiński University Clinical Center, Medical University of Silesia, 40-055 Katowice, Poland.

Article Synopsis
  • Corneal neovascularization can negatively affect vision and overall quality of life, driven by factors like vascular endothelial growth factor (VEGF).
  • Various treatments for this condition include conventional anti-VEGF therapies, laser interventions, and exploring new options like immunosuppressive drugs, antifibrotic agents, and innovative drug-delivery systems.
  • Recent advancements also involve gene therapies that target specific genes related to angiogenesis, emphasizing the importance of combination treatments and ongoing research to improve therapeutic effectiveness and minimize side effects.
View Article and Find Full Text PDF

Polycondensed Peptide-Based Polymers for Targeted Delivery of Anti-Angiogenic siRNA to Treat Endometriosis.

Int J Mol Sci

December 2023

Laboratory of Molecular Genetics and Gene Therapy, D.O. Ott Research Institute of Obstetrics, Gynecology and Reproductology, Mendeleevskaya Line 3, 199034 Saint-Petersburg, Russia.

Endometriosis (EM) is a prevalent gynecological disease characterized by the abnormal growth of tissue similar to the endometrium outside of the uterus. This condition is accompanied by the development of new blood vessels in endometriotic lesions. While surgical intervention is effective in removing endometriotic lesions, some patients require multiple surgeries.

View Article and Find Full Text PDF

A Synergistic Therapy With Antioxidant and Anti-VEGF: Toward its Safe and Effective Elimination for Corneal Neovascularization.

Adv Healthc Mater

February 2024

Xiamen University Affiliated Xiamen Eye Center, Eye Institute of Xiamen University, School of Medicine, Xiamen University, Xiamen, 361102, China.

Corneal neovascularization (CNV) is one of the leading causes of blindness in the world. In clinical practice; however, it remains a challenge to achieve a noninvasive and safe treatment. Herein, a biocompatible shell with excellent antioxidant and antivascularity is prepared by co-assembly of epigallocatechin gallate/gallic acid and Cu (II).

View Article and Find Full Text PDF

iRGD-Targeted Peptide Nanoparticles for Anti-Angiogenic RNAi-Based Therapy of Endometriosis.

Pharmaceutics

August 2023

Department of Genomic Medicine, D.O. Ott Research Institute of Obstetrics, Gynecology and Reproductology, Mendeleevskaya Line 3, 199034 Saint-Petersburg, Russia.

Anti-angiogenic RNAi-based therapy can be considered as a possible strategy for the treatment of endometriosis (EM), which is the most common gynecological disease. Targeted delivery of siRNA therapeutics is a prerequisite for successful treatment without adverse effects. Here we evaluated the RGD1-R6 peptide carrier as a non-viral vehicle for targeted siRNA delivery to endothelial cells in vitro and endometrial implants in vivo.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!